BDSX BIODESIX INC Insider Trading

10% owner Schuler buys 100,000 shares in 2 transactions totaling $1,180,736.00 at BDSX

Jack W Schuler, a 10% owner, executed 2 separate purchases totaling 100,000 shares for $1,180,736.00 (blended average $11.81) on 2026-01-23 and 2026-01-26, increasing his holdings to 1,563,210 shares. This $1.2M commitment by a major shareholder is notable in context: the company is unprofitable (net income $-8.7M in latest quarter) but shows strong revenue growth at +45.3% year-over-year, with current market cap of $88,148,989.80. Schuler's prior trades at BDSX exhibit a 4 of 4 well-timed pattern at the 90-day mark, including a particularly strong +1702.3% 30-day return and +1730.2% 90-day return on his 2025-08-29 purchase; his cross-ticker track record shows an 83.33% 90d win rate with an average 90d return of +1021.2%. The fresh accumulation by a 10% owner, combined with strong revenue momentum despite current losses, warrants monitoring of near-term price action and company profitability trajectory.

10% owner Jack W. Schuler buys 82,465 shares of BDSX at $10.96; holding rises to 1.46M shares; follows three consecutive measured buys all profitable at 90-day mark.

Jack W. Schuler, a 10% shareholder, purchased 82,465 shares at $10.96 on 2026-01-22, increasing his holdings by 6.0% to 1,463,210 shares total. The stock currently trades at $10.09, down 52.8% from its 52-week high of $21.40, though it has risen 48.0% over the past 30 days and 54.0% over 90 days. This buy follows a measurable pattern: his prior three BDSX purchases (2025-09-17, 2025-09-18, 2025-09-19) all generated positive 90-day returns (+30.7%, +22.2%, and +0.8% respectively), with 100% of measured prior buys at this ticker reaching positive outcomes at the 90-day mark. His broader cross-ticker track record shows 19 prior buys with an 83.33% 90-day win rate and average 90d return of +1021.2%, though the current purchase price ($10.96) significantly exceeds today's market price ($10.09), representing a -7.9% mark-to-market loss. BDSX remains unprofitable (net income of $-8.7M) but is growing revenue rapidly (+45.3% annually) with a market cap of $80.3M, suggesting a pre-revenue or early-stage profile despite the recent price recovery.

Director Schuler buys 142.0K BDSX shares at $7.04 (9/19/2025), expanding stake 11.5%; stock down 77.6% from 52-week high, but insider shows 85.71% win rate cross-ticker.

Director Jack W Schuler purchased 142,045 shares at $7.04 on 2025-09-19, increasing his BDSX holdings from 1,238,700 to 1,380,745 shares—a net addition of 11.5% to his existing position at a price now $1.04 below the current market price of $8.08. The transaction occurs with the stock trading at -77.6% from its 52-week high of $36.00 and down 10.9% over the past 30 days, yet Schuler's cross-ticker track record shows a 85.71% win rate with an average 90-day return of +1496.5% across 16 prior buys. At the same ticker (BDSX), Schuler's two prior measurable buy transactions completed on 2025-05-19 and 2025-05-16 both delivered exceptional outcomes: +2224.3% and +2868.2% over 90 days respectively, indicating a pattern of well-timed entries at BDSX specifically. The company itself remains unprofitable (net income of $-11,468,000.00 for the latest quarter) despite strong annual revenue growth of +45.3%, presenting a pre-profitability biotech investment backdrop where insider conviction and precise timing carry material weight.

Director Jack W Schuler purchases 18,373 shares (18.4K) at $6.04–$6.17 Sept 17–18; continues pattern of strong prior timing at BDSX.

Director Schuler executed two separate purchases totaling 18,373 shares for $111,425.34, lifting his holdings to 1,238,700 shares (1.5% increase). His prior trades at BDSX show a 90-day win rate of 3 of 3 measurable outcomes, with returns ranging from +1438.9% to +2868.2%, demonstrating consistent timing alignment with subsequent gains. Against a backdrop where the stock is down 80.2% from its 52-week high of $36.00 and has fallen 13.1% over 30 days, he accumulated at $6.04–$6.17, below the current price of $7.13. The company remains unprofitable (full-year net income $-11,468,000.00) but grew revenue 45.3% year-over-year at a $1.0B market cap, suggesting a growth-stage valuation under pressure. His sustained accumulation following a pattern of well-timed buys at the same ticker signals continued conviction, though near-term volatility and the company's ongoing losses merit observation.

BDSX Director Jack W Schuler buys 3,488,372 shares at $0.43 on 2025-08-29, expanding stake 16.7%; stock now $8.44, up 49.8% in 90 days

Jack W Schuler, a director of BIODESIX, purchased 3,488,372 shares at $0.43 per share on 2025-08-29, expanding his holdings from 20,918,174 shares to 24,406,546 shares—a 16.7% increase. This represents a material accumulation at a price significantly below the current market price of $8.44, which suggests the transaction occurred during a period of depressed valuations. His prior five purchases at BDSX all yielded positive 90-day returns ranging from +1382.7% to +2868.2%, with 5 of 5 prior buys well-timed at the 90-day mark; however, the company remains unprofitable (net income of -$11,468,000 on revenue of $20,018,000) despite 45.3% annual revenue growth. The timing and scale of this purchase, combined with the director's historical success rate at this ticker, merit scrutiny—but the underlying financial distress and current price movement context (stock trading -78.5% from its 52-week high) warrant assessment of whether past returns reflect durable signals or volatile recovery patterns.

Director Jack W. Schuler bought 4,723,239 shares for $1,316,624.50 at blended $0.28; holdings +29.2% to 20.92M; stock down 86.2% from 52-week high.

Director Jack W. Schuler made two separate purchases totaling 4,723,239 shares for $1,316,624.50, expanding his holdings by 29.2% to 20.92M shares. These buys occurred at $0.27 (4,000,000 shares on 2025-05-16) and $0.34 (723,239 shares on 2025-05-19), a blended average of $0.28, while the stock has collapsed 86.2% from its 52-week high of $39.20 and dropped 50.6% over the prior 30 days. Schuler's same-ticker trading record shows 3 prior measurable buys at BDSX, all of which registered strong 90-day returns (ranging from +1382.7% to +1558.5%), establishing a pattern of well-timed entry points at this specific ticker. The company remains unprofitable with net income of $-11,101,000.00 against revenue of $17,958,000.00 (latest quarter), yet revenue is growing at +45.3% year-over-year, creating a contrasting backdrop of operational momentum and financial losses.

Director Jack W Schuler bought 100,000 shares of BDSX at $1.23 on 2024-11-21; stock now $25.60, -39.6% from 52-week high

Jack W Schuler, a Director, purchased 100,000 shares at $1.23 on 2024-11-21, continuing a pattern of repeated open-market buys at this ticker—he has executed 5 prior buys at BDSX, with 2 occurring just days earlier (2024-11-20 and 2024-11-05). The current stock price of $25.60 is -39.6% from the 52-week high and has fallen -19.0% over the last 30 days and -29.3% over 90 days, suggesting Schuler is accumulating shares through a period of sustained price decline. While Schuler's cross-ticker track record shows an average 90d return of +501.4% on prior buys, the same-ticker history at BDSX offers no measurable outcomes yet (all 5 prior BDSX trades remain too recent to evaluate). The company generated $18.2M in quarterly revenue with -$10.3M net income, remains unprofitable on a full-year basis, but shows +28.5% annual revenue growth. The repeated buys amid a sharp drawdown and sustained unprofitability warrant monitoring of whether this signals conviction or accumulation in a challenged capital structure.

Director Kennedy Lawrence T. Jr bought 35,000 shares of BDSX at $1.16 on 2024-11-21; stock down 39.6% from 52-week high.

Kennedy Lawrence T. Jr., a director holding 10.41M shares post-transaction, purchased 35,000 shares at $1.16 on 2024-11-21, representing a $40.6K outlay. This is his third open-market buy across all tickers; at BDSX specifically, he also bought on 2024-11-05 and 2024-11-06, indicating repeated accumulation within a 16-day window. The stock has declined 39.6% from its 52-week high and fallen 19.0% over the past 30 days, placing the purchase price substantially below recent market levels. BDSX is unprofitable on a full-year basis with net income of $-10.3M against quarterly revenue of $18.2M, though annual revenue growth reached 28.5%. The director's concentrated position (10.41M shares represents substantial ownership) and sequential purchases at depressed price levels warrant monitoring to understand whether the pattern reflects conviction in recovery or other strategic considerations.

BDSX director Jack W Schuler bought 200,000 shares at $1.17 on 2024-11-20; stock down -25.5% in 30d and -33.7% in 90d.

Jack W Schuler, a director of BIODESIX INC, purchased 200,000 shares at $1.17 on 2024-11-20, bringing his holdings to 31.09M shares. This buy occurs in a declining market context: the stock is down -25.5% over the prior 30 days and -33.7% over 90 days, trading -43.4% below its 52-week high of $42.40. The purchase price of $1.17 is significantly below the current price of $24.00, suggesting the transaction occurred at a substantial discount to present levels. BIODESIX remains unprofitable (net income $-10.3M in the latest quarter) despite quarterly revenue of $18.2M and 28.5% annual revenue growth. Schuler's cross-ticker track record shows positive average returns of +620.4% at 30 days and +501.4% at 90 days (50.0% win rate), but his prior 5 trades at BDSX have not yet reached measurable 30- or 90-day outcome windows, providing no same-ticker precedent for evaluating timing accuracy at this specific security.

BDSX Director PATIENCE JOHN buys 75,000 shares at $1.38; cluster buy with 4 others in 14 days as stock down 21.3% in 30 days.

Director John Patience purchased 75,000 shares at $1.38 on 2024-11-05, increasing his holdings to 2,153,298 shares. This transaction is part of a broader cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated confidence among the leadership group. However, context is important: the stock has fallen 21.3% over the past 30 days and 18.9% over 90 days, trading at $26.60 against a 52-week high of $42.40. Patience's own cross-ticker track record shows 1 prior buy with a 90-day win rate of 0.00%, suggesting his past discretionary purchases have not resulted in gains within that timeframe. The company remains unprofitable on a full-year basis despite 28.5% annual revenue growth, creating fundamental uncertainty alongside the recent price pressure.